Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

OncoMed Cancer Candidate Fails Trial, Bayer Opts Out Of Deal

Published 04/11/2017, 06:05 AM
Updated 07/09/2023, 06:31 AM

It was a bad day for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) as it suffered two setbacks.

The company’s pipeline candidate demcizumab (anti-DLL4, OMP-21M18) failed to meet its primary endpoint of progression free survival in a phase II YOSEMITE study in first-line treatment of patients with metastatic pancreatic cancer. The candidate was being evaluated in combination with Celgene Corporation’s (NASDAQ:CELG) drug Abraxane plus gemcitabine.

The other bad news that Oncomed faced was that Bayer Pharma -a subsidiary of Bayer Aktiengesellschaft (OTC:BAYRY) notified the former of its decision not to exercise its option to license the first-in-class Wnt pathway inhibitors vantictumab and ipafricept.

Shares of the company declined 37% on Monday in response to the negative news. In-fact, OncoMed’s recent share price movement shows that the company has underperformed the Zacks classified Medical - Biomedical and Genetics industry year to date. The stock declined 33.5% as against the industry’s gain of 2.6% during the period.

Coming back to the release, the YOSEMITEstudy failed to show benefit over standard-of-care.

The interim median overall survival for patients receiving either one or two truncated courses of demcizumab in combination with Abraxane plus gemcitabine was 13.2 months, and the median overall survival was not reached for the Abraxane, gemcitabine plus placebo arm.

Moving ahead, OncoMed will conduct additional analysis along with its partner Celgene), to understand these outcomes. Additionally, the company will discontinue any additional enrollment in its other ongoing demcizumab trials and conduct analyses of the data from those trials as planned.

After Bayer pulled out of the deal, Oncomed stated that it will retain worldwide development and commercialization rights to vantictumab, ipafricept and all other Wnt pathway biologics under the collaboration effective Jun 27. Vantictumab and ipafricept are selective inhibitors of the Wnt pathway.

The company is on the verge of completing two phase Ib combination clinical trials of vantictumab – one in HER2-negative breast cancer and another in advanced pancreatic cancer and two phase Ib combination clinical trials of ipafricept – one in ovarian cancer and the other in pancreatic cancer.

Per the deal with Bayer, OncoMed received over $90 million in upfront and milestone payments that have fully funded the development of vantictumab and ipafricept.

Zacks Rank & Stocks to Consider

OncoMed currently carries a Zacks Rank #2 (Hold). Another favorable stock in the health care sector includes Heska Corp. (NASDAQ:HSKA) carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Heska’s earnings estimates moved up from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 60 days. The company posted a positive earnings surprise in all of the last four quarters, with an average beat of 291.54%. Its share price increased 40.7% year to date.

Looking for Ideas with Even Greater Upside?

Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>



Bayer AG (DE:BAYGN) (BAYRY): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

OncoMed Pharmaceuticals, Inc. (OMED): Free Stock Analysis Report

Heska Corporation (HSKA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.